We are investigating OvaScience, Inc. (“OvaScience” or the “Company”) (NasdaqCM: OVAS) relating to the merger of the Company with Millendo Therapeutics. As a result of the agreement, OvaScience shareholders will own approximately 20% of the combined company and current Millendo investors will own approximately 80% of the combined company.